Medtronic Symplicity Study Shows Blood Pressure Drops
Medtronic says nearly nine out of 10 patients experienced a clinical benefit at six months in the SPYRAL AFFIRM real-world study. The company received FDA approval for a U.S. labeling update to its Symplicity procedure.
Story updates
07:36:15 PM UTC
SquawkNews
Medtronic reported statistically significant blood pressure reductions at six months in the SPYRAL AFFIRM study, with no increase in antihypertensive medications. The FDA approved a labeling update adding clinical data for patients with isolated systolic hypertension, CKD up to stage 3b and type 2…
07:37:43 PM UTC
SquawkNews
SPYRAL AFFIRM post-approval study met its primary endpoint, showing statistically significant 6-mont